دورية أكاديمية
أعرض في EDS

Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.

التفاصيل البيبلوغرافية
العنوان: Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
المؤلفون: González-Barca E; Institut Català d'Oncologia. IDIBELL., Hospital Duran i Reynals, Av. Gran Vía 199-203, 08908, L'Hospitalet de Llobregat, Barcelona, Spain. e.gonzalez@iconcologia.net., Canales M; Hospital Universitario La Paz, Madrid, Spain., Salar A; Hospital del Mar, Barcelona, Spain., Ferreiro-Martínez JJ; Hospital Donostia, San Sebastián, Spain., Ferrer-Bordes S; Hospital Dr. Peset, Valencia, Spain., García-Marco JA; Hospital Puerta de Hierro, Madrid, Spain., Sánchez-Blanco JJ; Hospital Morales Meseguer, Murcia, Spain., García-Frade J; Hospital Río Hortega, Valladolid, Spain., Peñalver J; Fundación Hospital de Alcorcón, Madrid, Spain., Bello-López JL; Complexo Hospitalario de Santiago, Santiago de Compostela, Spain., Sancho JM; Institut Català d'Oncologia - Hospital Germans Trias i Pujol, Badalona, Spain., Caballero D; Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
مؤلفون مشاركون: GELTAMO group
المصدر: Annals of hematology [Ann Hematol] 2016 May; Vol. 95 (6), pp. 893-9. Date of Electronic Publication: 2016 Mar 30.
نوع المنشور: Journal Article; Multicenter Study
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
مواضيع طبية MeSH: Antimetabolites, Antineoplastic/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Cytarabine/*administration & dosage , Lymphoma, Large B-Cell, Diffuse/*diagnosis , Lymphoma, Large B-Cell, Diffuse/*drug therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Injections, Spinal ; Lymphoma, Large B-Cell, Diffuse/mortality ; Male ; Middle Aged ; Post-Exposure Prophylaxis/methods ; Prednisone/administration & dosage ; Prospective Studies ; Risk Factors ; Rituximab ; Survival Rate ; Vincristine/administration & dosage ; Young Adult
مستخلص: The dissemination in the central nervous system (CNS) is an uncommon but fatal complication occurring in patients with diffuse large B-cell lymphoma (DLBCL). Standard prophylaxis has been demonstrated to reduce CNS relapse and improve survival rates. Intrathecal (IT) liposomal cytarabine allows maintaining elevated drug levels in the cerebrospinal fluid for an extended period of time. Data on the efficacy and safety of liposomal cytarabine as CNS prophylaxis in patients with DLBCL are still insufficient. The objective of the present study was to evaluate the effectiveness and safety of the prophylaxis with IT liposomal cytarabine in prevention of CNS relapse in high-risk patients with DLBCL who were included in a trial of first line systemic therapy with 6 cycles of dose-dense R-CHOP every 14 days. Twenty-four (18.6 %) out of 129 patients were identified to have risk factors for CNS involvement, defined as follows: >30 % bone marrow infiltration, testes infiltration, retroperitoneal mass ≥10 cm, Waldeyer ring, or bulky cervical nodes involvement. Liposomal cytarabine (50 mg) was administered by lumbar puncture the first day of the 1st, 2nd, and 6th cycle of R-CHOP14 scheme. Among 70 IT infusions, grade 3-4 adverse events reported were headache (one patient) and nausea/vomiting (one patient). With a median follow-up of 40.1 months, no CNS involvement by DLBCL was observed in any patient. In conclusion, IT liposomal cytarabine is safe, feasible, and effective for CNS prophylaxis, causing few associated risks and little discomfort to patients with DLBCL.
References: Blood. 2005 Jan 15;105(2):496-502. (PMID: 15358629)
Blood. 2004 Nov 15;104(10):3009-20. (PMID: 15265787)
Med Clin (Barc). 2016 Jan 15;146(2):74-80. (PMID: 25817451)
J Clin Oncol. 2005 Jun 20;23(18):4117-26. (PMID: 15867204)
Hematol Oncol Clin North Am. 2005 Aug;19(4):597-609, v. (PMID: 16083825)
Lancet Oncol. 2006 May;7(5):379-91. (PMID: 16648042)
Ann Oncol. 2007 Jan;18(1):149-57. (PMID: 17018708)
Blood. 2007 Apr 15;109(8):3214-8. (PMID: 17209054)
Ann Oncol. 2007 Jun;18(6):1085-9. (PMID: 17363838)
Expert Opin Pharmacother. 2008 Feb;9(2):301-9. (PMID: 18201152)
J Clin Oncol. 2009 Jan 1;27(1):114-9. (PMID: 19047289)
Blood. 2009 Apr 23;113(17):3896-902. (PMID: 19144985)
Cancer. 2009 May 1;115(9):1892-8. (PMID: 19235254)
Int J Hematol. 2009 Jun;89(5):577-83. (PMID: 19353238)
Cancer. 2010 May 15;116(10):2290-300. (PMID: 20209620)
Ann Oncol. 2010 May;21 Suppl 5:v172-4. (PMID: 20555073)
Cancer. 2010 Sep 15;116(18):4283-90. (PMID: 20564149)
Haematologica. 2011 Feb;96(2):238-44. (PMID: 20952517)
Haematologica. 2011 Jul;96(7):1002-7. (PMID: 21486867)
Crit Rev Oncol Hematol. 2011 Sep;79(3):330-43. (PMID: 21273093)
Curr Opin Oncol. 2011 Sep;23(5):436-40. (PMID: 21760506)
Lancet. 2011 Nov 26;378(9806):1858-67. (PMID: 22118442)
Br J Haematol. 2012 Jan;156(2):234-44. (PMID: 22098541)
Ann Oncol. 2012 May;23(5):1267-73. (PMID: 21989328)
Br J Haematol. 2012 Oct;159(1):39-49. (PMID: 22849793)
Ann Oncol. 2013 May;24(5):1385-92. (PMID: 23247661)
Lancet. 2013 May 25;381(9880):1817-26. (PMID: 23615461)
Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. (PMID: 23375551)
Pol Arch Med Wewn. 2013;123(11):589-95. (PMID: 23928849)
Br J Haematol. 2014 May;165(3):358-63. (PMID: 24467658)
Leuk Lymphoma. 2014 Oct;55(10):2228-40. (PMID: 24286262)
Br J Haematol. 2015 Mar;168(5):654-62. (PMID: 25312994)
Ann Hematol. 2015 Nov;94(11):1859-63. (PMID: 26280395)
J Clin Oncol. 1999 Apr;17(4):1244. (PMID: 10561185)
N Engl J Med. 2002 Jan 24;346(4):235-42. (PMID: 11807147)
Ann Oncol. 2002 Jul;13(7):1099-107. (PMID: 12176790)
J Clin Oncol. 2003 Jan 1;21(1):20-7. (PMID: 12506165)
Cancer. 2003 Jun 15;97(12):3053-60. (PMID: 12784341)
Br J Haematol. 2004 Jan;124(2):151-9. (PMID: 14687024)
J Clin Oncol. 1995 Oct;13(10):2656-75. (PMID: 7595720)
Blood. 1995 Sep 15;86(6):2091-7. (PMID: 7662956)
J Clin Oncol. 1993 Nov;11(11):2186-93. (PMID: 8229133)
J Clin Oncol. 1999 Oct;17(10):3110-6. (PMID: 10506606)
Expert Rev Neurother. 2004 Jul;4(4 Suppl):S19-24. (PMID: 15853551)
فهرسة مساهمة: Keywords: Central nervous system; Diffuse large B-cell lymphoma; Liposomal cytarabine; Prophylaxis
المشرفين على المادة: 0 (Antibodies, Monoclonal, Murine-Derived)
0 (Antimetabolites, Antineoplastic)
0 (R-CHOP protocol)
04079A1RDZ (Cytarabine)
4F4X42SYQ6 (Rituximab)
5J49Q6B70F (Vincristine)
80168379AG (Doxorubicin)
8N3DW7272P (Cyclophosphamide)
VB0R961HZT (Prednisone)
تواريخ الأحداث: Date Created: 20160331 Date Completed: 20170127 Latest Revision: 20191210
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC4853453
DOI: 10.1007/s00277-016-2648-4
PMID: 27025508
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا